NISKAYUNA, N.Y.--(BUSINESS WIRE)--Vanderbilt University has partnered with GE Global Research, the technology development arm for the General Electric Company (NYSE: GE), to better define – at the cellular level – how colon tumors form and develop. The research, supported by a five-year, $3.75 million grant from the Office of the Director of the National Institutes of Health (NIH), will test GE’s revolutionary cancer mapping technology, an automated platform that can probe and analyze up to 60 different disease markers, including proteins and messenger RNAs, in a single tissue sample. The ability to study dozens of markers at one time provides a more complete picture of what’s happening with the cancer. Currently, a diagnosis of cancer and the decision of which therapy to prescribe are based on the histology of the tumor and, in some cases, the expression of just one or two disease markers inside a patient’s tumor.
